Targeting age-related macular degeneration with Alzheimer's disease based immunotherapies:: Anti-amyloid-β antibody attenuates pathologies in an age-related macular degeneration mouse model
Targeting age-related macular degeneration with Alzheimer's disease based immunotherapies:: Anti-amyloid-β antibody attenuates pathologies in an age-related macular degeneration mouse model
复制标题
DOI：
10.1016/j.visres.2007.07.025
复制
发表时间：
2008-02-01
期刊：
影响因子：
1.8
通讯作者：
Rickman, Catherine Bowes
中科院分区：
文献类型：
--
作者：
Ding, Jin-Dong;Lin, John;Rickman, Catherine Bowes
阿尔茨海默病相关性黄斑变性（AMD）是一种迟发性神经退行性视网膜疾病，其与阿尔茨海默病（AD）具有若干临床和病理特征，包括含有淀粉样蛋白-β（A β）肽的细胞外沉积物。已经研究了靶向A β蛋白的免疫疗法作为AD的潜在治疗。在这里，我们提出了扩展这种方法来治疗AMD的基本原理。我们在AMD小鼠模型中测试了全身施用的抗A β抗体。与对照组相比，治疗组动物的组织学和功能测量显示，免疫治疗后，视网膜和脑中A β的量减少，视网膜中的ERG缺陷减弱。这些数据支持A β是AMD治疗靶点的假设。(c)2007爱思唯尔有限公司保留所有权利。
Age-related macular degeneration (AMD) is a late-onset, neurodegenerative retinal disease that shares several clinical and pathological features with Alzheimer's disease (AD) including extracellular deposits containing amyloid-beta (A beta) peptides. Immunotherapy targeting the A beta protein has been investigated as a potential treatment for AD. Here, we present the rationale for extending this approach to treat AMD. We tested an anti-A beta antibody administered systemically in a mouse model of AMD. Histological and functional measurements in treated animals compared to controls showed that following immunotherapy, the amounts of A beta in the retina and brain were decreased and the ERG deficits in the retina were attenuated. These data support the hypothesis that A beta is a therapeutic target for AMD. (c) 2007 Elsevier Ltd. All rights reserved.